- Embolization Devices
- Ablation Devices
- Support Devices
Interventional Oncology Market size was valued at USD 2.1 billion in 2022, It is expected to reach a value of USD 3.2 billion by 2029, growing at a CAGR of 6.8% from 2023 to 2029. The global market provides a detailed overview of the Interventional Oncology Market, which has been segmented by product, ablation device, support devices, procedure, cancer type, and end user. The interventional oncology market has been segmented into In Embolization Devices (Radioembolic Agents, Non-Radio embolic Agents (Microspheres, Coated Beads, Microparticles). The Embolization Devices segment is likely the most significant and fastest-growing segment in various products. By ablation devices, the interventional oncology market has been segmented into Radiofrequency (RF) Ablation Devices, Microwave Ablation Devices, Cryoablation Devices, and Other Ablation Devices. The Radiofrequency (RF) Ablation Devices are expected to account for a significant revenue share during the forecast period. Support devices have segmented the interventional oncology market into Microcatheters, Guidewires. The Microcatheters accounted for a substantial revenue share in 2021. By Procedure, the interventional oncology market has been segmented into Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, Transcatheter Arterial Embolization/Bland Embolization. Thermal Tumor Ablation is expected to hold a significant revenue share during the forecast period. The interventional oncology market has been segmented by cancer types: Liver Cancer, Lung Cancer, Bone Metastasis, Kidney Cancer, Breast Cancer, Prostate Cancer, and Other Cancers. The liver cancer segment holds the largest revenue share of the interventional oncology market. Based on the End User, Interventional Oncology is segmented into Hospitals, Ambulatory Surgery Centers, and Research & Academic Institutes. The Hospitals segment is predicted to register the fastest growth rate during the forecast period, according to precision business insights.
Interventional Oncology Market Key Developments:
In 2021, Boston Scientific (US) launched the TheraSphere Y-90 Glass Microspheres.
Interventional Oncology Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
6.8%
Largest Market
North American
Fastest Growing Market
Asia-Pacific
Interventional Oncology Market Dynamics
According to the World Health Organization (WHO), cancer kills 8.3 million people annually, with 70 % of new cancer cases likely to be recorded in the next 20 years. A rise in cancer patients is expected to be a significant market driver.
North America Got Significant Share
Interventional Oncology Market Regional Analysis
The interventional oncology market is divided into five geographic segments: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In terms of region, North America held the largest market share for interventional oncology worldwide in 2021.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The interventional oncology market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Interventional Oncology Market Segmentation
By Product
By Procedure
- Thermal Tumor Ablation
- Non-Thermal Tumor Ablation
- Transcatheter Arterial Chemoembolization
- Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
- Transcatheter Arterial Embolization/Bland Embolization
By Cancer Type
- Liver Cancer
- Lung Cancer
- Bone Metastasis
- Kidney Cancer
- Breast Cancer
- Prostate Cancer
- Other Cancers
By End User
- Hospitals
- Ambulatory Surgery Centers
- Research & Academic Institutes
Frequently Asked Questions
The Interventional Oncology Market is projected to expand at a CAGR of 6.8% during the forecast period
The major global Interventional Oncology market players are ??? Medtronic, AngioDynamics, HealthTronics, Boston Scientific, J&J, BD, Teleflex, Terumo, Cook Medical, and Merit Medical.
North American is the fastest-growing region for Interventional Oncology Market
| 1. Executive Summary |
| 2. Global Interventional Oncology Market Introduction |
| 2.1. Global Interventional Oncology Market - Taxonomy |
| 2.2. Global Interventional Oncology Market -Definitions |
| 2.2.1. By Product |
| 2.2.2. By Procedure |
| 2.2.3. By Cancer Type |
| 2.2.4. By End User |
| 2.2.5. By Region |
| 3. Global Interventional Oncology Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Interventional Oncology Market Dynamic Factors - Impact Analysis |
| 3.6. Global Interventional Oncology Market - Competition Landscape |
| 4. Global Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Interventional Oncology Market, By Product, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1. Embolization Devices |
| 5.1.1. Radioembolic Agents |
| 5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Non-Radio embolic Agents |
| 5.1.2.1. Microspheres |
| 5.1.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.1.3. Market Opportunity Analysis |
| 5.1.2.2. Coated Beads |
| 5.1.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.2.3. Market Opportunity Analysis |
| 5.1.2.3. Microparticles |
| 5.1.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.1.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3.3. Market Opportunity Analysis |
| 5.2. Ablation Devices |
| 5.2.1. Radiofrequency (RF) Ablation Devices |
| 5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Microwave Ablation Devices |
| 5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Cryoablation Devices |
| 5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.2.4. Other Ablation Devices |
| 5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.4.3. Market Opportunity Analysis |
| 5.3. Support Devices |
| 5.3.1. Microcatheters |
| 5.3.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Guidewires |
| 5.3.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 6. Global Interventional Oncology Market, By Procedure, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1. Thermal Tumor Ablation |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Non-Thermal Tumor Ablation |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Transcatheter Arterial Chemoembolization |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Transcatheter Arterial Embolization/Bland Embolization |
| 6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Interventional Oncology Market, By Cancer Type, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1. Liver Cancer |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Lung Cancer |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Bone Metastasis |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Kidney Cancer |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Breast Cancer |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Prostate Cancer |
| 7.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 7.7. Other Cancers |
| 7.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.7.3. Market Opportunity Analysis |
| 8. Global Interventional Oncology Market, By End User, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Ambulatory Surgery Centers |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Research & Academic Institutes |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Interventional Oncology Market Forecast, By Region, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Region, 2023-2029 |
| 10. North America Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 10.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Embolization Devices |
| 10.1.1.1. Radioembolic Agents |
| 10.1.1.2. Non-Radio embolic Agents |
| 10.1.1.2.1. Microspheres |
| 10.1.1.2.2. Coated Beads |
| 10.1.1.2.3. Microparticles |
| 10.1.2. Ablation Devices |
| 10.1.2.1. Radiofrequency (RF) Ablation Devices |
| 10.1.2.2. Microwave Ablation Devices |
| 10.1.2.3. Cryoablation Devices |
| 10.1.2.4. Other Ablation Devices |
| 10.1.3. Support Devices |
| 10.1.3.1. Microcatheters |
| 10.1.3.2. Guidewires |
| 10.2. Procedure Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Thermal Tumor Ablation |
| 10.2.2. Non-Thermal Tumor Ablation |
| 10.2.3. Transcatheter Arterial Chemoembolization |
| 10.2.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 10.2.5. Transcatheter Arterial Embolization/Bland Embolization |
| 10.3. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Liver Cancer |
| 10.3.2. Lung Cancer |
| 10.3.3. Bone Metastasis |
| 10.3.4. Kidney Cancer |
| 10.3.5. Breast Cancer |
| 10.3.6. Prostate Cancer |
| 10.3.7. Other Cancers |
| 10.4. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Hospitals |
| 10.4.2. Ambulatory Surgery Centers |
| 10.4.3. Research & Academic Institutes |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. USA |
| 10.5.2. Canada |
| 10.6. North America Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Country, 2023-2029 |
| 10.7. North America Interventional Oncology Market Dynamics - Trends |
| 11. Europe Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 11.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Embolization Devices |
| 11.1.1.1. Radioembolic Agents |
| 11.1.1.2. Non-Radio embolic Agents |
| 11.1.1.2.1. Microspheres |
| 11.1.1.2.2. Coated Beads |
| 11.1.1.2.3. Microparticles |
| 11.1.2. Ablation Devices |
| 11.1.2.1. Radiofrequency (RF) Ablation Devices |
| 11.1.2.2. Microwave Ablation Devices |
| 11.1.2.3. Cryoablation Devices |
| 11.1.2.4. Other Ablation Devices |
| 11.1.3. Support Devices |
| 11.1.3.1. Microcatheters |
| 11.1.3.2. Guidewires |
| 11.2. Procedure Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Thermal Tumor Ablation |
| 11.2.2. Non-Thermal Tumor Ablation |
| 11.2.3. Transcatheter Arterial Chemoembolization |
| 11.2.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 11.2.5. Transcatheter Arterial Embolization/Bland Embolization |
| 11.3. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Liver Cancer |
| 11.3.2. Lung Cancer |
| 11.3.3. Bone Metastasis |
| 11.3.4. Kidney Cancer |
| 11.3.5. Breast Cancer |
| 11.3.6. Prostate Cancer |
| 11.3.7. Other Cancers |
| 11.4. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Hospitals |
| 11.4.2. Ambulatory Surgery Centers |
| 11.4.3. Research & Academic Institutes |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Spain |
| 11.5.5. Italy |
| 11.5.6. Russia |
| 11.5.7. Rest of Europe |
| 11.6. Europe Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Country, 2023-2029 |
| 11.7. Europe Interventional Oncology Market Dynamics - Trends |
| 12. Asia-Pacific Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 12.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Embolization Devices |
| 12.1.1.1. Radioembolic Agents |
| 12.1.1.2. Non-Radio embolic Agents |
| 12.1.1.2.1. Microspheres |
| 12.1.1.2.2. Coated Beads |
| 12.1.1.2.3. Microparticles |
| 12.1.2. Ablation Devices |
| 12.1.2.1. Radiofrequency (RF) Ablation Devices |
| 12.1.2.2. Microwave Ablation Devices |
| 12.1.2.3. Cryoablation Devices |
| 12.1.2.4. Other Ablation Devices |
| 12.1.3. Support Devices |
| 12.1.3.1. Microcatheters |
| 12.1.3.2. Guidewires |
| 12.2. Procedure Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Thermal Tumor Ablation |
| 12.2.2. Non-Thermal Tumor Ablation |
| 12.2.3. Transcatheter Arterial Chemoembolization |
| 12.2.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 12.2.5. Transcatheter Arterial Embolization/Bland Embolization |
| 12.3. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Liver Cancer |
| 12.3.2. Lung Cancer |
| 12.3.3. Bone Metastasis |
| 12.3.4. Kidney Cancer |
| 12.3.5. Breast Cancer |
| 12.3.6. Prostate Cancer |
| 12.3.7. Other Cancers |
| 12.4. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Hospitals |
| 12.4.2. Ambulatory Surgery Centers |
| 12.4.3. Research & Academic Institutes |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. China |
| 12.5.2. India |
| 12.5.3. Japan |
| 12.5.4. ASEAN |
| 12.5.5. Australia & New Zealand |
| 12.5.6. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Country, 2023-2029 |
| 12.7. Asia-Pacific Interventional Oncology Market Dynamics - Trends |
| 13. Latin America Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 13.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Embolization Devices |
| 13.1.1.1. Radioembolic Agents |
| 13.1.1.2. Non-Radio embolic Agents |
| 13.1.1.2.1. Microspheres |
| 13.1.1.2.2. Coated Beads |
| 13.1.1.2.3. Microparticles |
| 13.1.2. Ablation Devices |
| 13.1.2.1. Radiofrequency (RF) Ablation Devices |
| 13.1.2.2. Microwave Ablation Devices |
| 13.1.2.3. Cryoablation Devices |
| 13.1.2.4. Other Ablation Devices |
| 13.1.3. Support Devices |
| 13.1.3.1. Microcatheters |
| 13.1.3.2. Guidewires |
| 13.2. Procedure Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Thermal Tumor Ablation |
| 13.2.2. Non-Thermal Tumor Ablation |
| 13.2.3. Transcatheter Arterial Chemoembolization |
| 13.2.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 13.2.5. Transcatheter Arterial Embolization/Bland Embolization |
| 13.3. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Liver Cancer |
| 13.3.2. Lung Cancer |
| 13.3.3. Bone Metastasis |
| 13.3.4. Kidney Cancer |
| 13.3.5. Breast Cancer |
| 13.3.6. Prostate Cancer |
| 13.3.7. Other Cancers |
| 13.4. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Hospitals |
| 13.4.2. Ambulatory Surgery Centers |
| 13.4.3. Research & Academic Institutes |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Rest of Latin America |
| 13.6. Latin America Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Country, 2023-2029 |
| 13.7. Latin America Interventional Oncology Market Dynamics - Trends |
| 14. Middle East and Africa Interventional Oncology Market Analysis, 2018-2022 and Forecast, 2023-2029 (Revenue, USD Mn) |
| 14.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Embolization Devices |
| 14.1.1.1. Radioembolic Agents |
| 14.1.1.2. Non-Radio embolic Agents |
| 14.1.1.2.1. Microspheres |
| 14.1.1.2.2. Coated Beads |
| 14.1.1.2.3. Microparticles |
| 14.1.2. Ablation Devices |
| 14.1.2.1. Radiofrequency (RF) Ablation Devices |
| 14.1.2.2. Microwave Ablation Devices |
| 14.1.2.3. Cryoablation Devices |
| 14.1.2.4. Other Ablation Devices |
| 14.1.3. Support Devices |
| 14.1.3.1. Microcatheters |
| 14.1.3.2. Guidewires |
| 14.2. Procedure Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Thermal Tumor Ablation |
| 14.2.2. Non-Thermal Tumor Ablation |
| 14.2.3. Transcatheter Arterial Chemoembolization |
| 14.2.4. Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy |
| 14.2.5. Transcatheter Arterial Embolization/Bland Embolization |
| 14.3. Cancer Type Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Liver Cancer |
| 14.3.2. Lung Cancer |
| 14.3.3. Bone Metastasis |
| 14.3.4. Kidney Cancer |
| 14.3.5. Breast Cancer |
| 14.3.6. Prostate Cancer |
| 14.3.7. Other Cancers |
| 14.4. End User Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Hospitals |
| 14.4.2. Ambulatory Surgery Centers |
| 14.4.3. Research & Academic Institutes |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Gulf Cooperation Council (GCC) Countries |
| 14.5.2. South Africa |
| 14.5.3. Rest of MEA |
| 14.6. MEA Interventional Oncology Market - Opportunity Analysis Index, By Product, Procedure, Cancer Type, End User, and Country, 2023-2029 |
| 14.7. MEA Interventional Oncology Market Dynamics - Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 15.2.1. Boston Scientific Corporation |
| 15.2.2. Medtronic PLC |
| 15.2.3. Terumo Corporation |
| 15.2.4. Merit Medical Systems Inc. |
| 15.2.5. CR Bard Inc. |
| 15.2.6. Profound Medical Corp. |
| 15.2.7. AngioDynamics Inc. |
| 15.2.8. Cook Medical LLC |
| 15.2.9. HealthTronics Inc. |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Boston Scientific Corporation
- Medtronic PLC
- Terumo Corporation
- Merit Medical Systems Inc.
- CR Bard Inc.
- Profound Medical Corp.
- AngioDynamics Inc.
- Cook Medical LLC
- HealthTronics Inc.